Avoiding problems in clinical practice after the pill scare

Human Reproduction Update

Volumn 5, Issue 6, 1999, Pages 639-653

  Mills, Angela ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Combined oral contraceptive; Communication; Contraception; Pill scare; Public health

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT;

CLINICAL PRACTICE; DRUG INFORMATION; DRUG SAFETY; FEMALE; HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK; RISK BENEFIT ANALYSIS; VEIN THROMBOSIS;

EID: 0033402463     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/5.6.639     Document Type: Review

References (69)

1. Bagwell, M.A., Coker, A.L., Thompson, S.J. et al. (1995) Primary infertility and oral contraceptive steroid use. Fertil. Steril., 63, 1161-1166.
2. Benagiano, G. (1998) Learning from the past: venous thromboembolism and the pill. An endless saga. Hum. Reprod., 13, 1115-1116.
3. Bloemenkamp, K.W.M., Rosendaal, F.R., Helmerhorst, F.M. et al. (1995) Enhancement of factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestogen. Lancet, 1995, 346, 1593-1596.
4. Cancer and Steroid Hormone study (CASH study) of the Centers for Disease Control and the National Institute of Child Health and human Development (1987) The reduction in risk of ovarian cancer associated with oral contraceptive use. N. Engl. J. Med., 316, 650-655.
5. Carlson, K.J. (1997) Outcomes of hysterectomy. Clin. Obstet. Gynecol., 40, 939-946.
6. Committee on Safety of Medicines. Combined oral contraceptives and thromboembolism. Letter, October 17, 1995.
7. Crook, D. and Godsland, I. (1998) Safety evaluation of modern oral contraceptives: effects on lipoprotein and carbohydrate metabolism. Contraception, 57, 189-202.
8. Davies, J. (1998) Women must wake up to the peril of the pill. The Mail on Sunday. February 22, p. 39.
9. Drife, J.O. (1989) The benefits of combined oral contraceptives. Br. J. Obstet. Gynaecol., 96, 1225-1228.
10. Edwards, R.G., Beard, H.K. and Bradshaw, J.P. (1997) Balancing the risks and benefits of oral contraception. Hum. Reprod, 12, 2339-2340.
11. Entre Nous (1990) The European Family Planning Magazine, 16, September.
12. Family Planning Association (1987) Ovarian cancer and The Pill. Press release.
13. Farley, T.M.M., Colins, J. and Schlesselman, J.J. (1998) Hormonal contraception and risk of cardiovascular disease. Contraception, 57, 211-230.
14. Farquar, I.V. and Jepson, R. (1997) The effectiveness of oral contraceptive pills versus placebo or any other medical treatment for menorrhagia. The Cochrane Library, Issue 3, 1-7.
15. FASS 98 (Läkemedel i Sverige), publ:Läkemedelsinformation AB, Box 17608, 118 92 Stockholm. Fax +46 8 4620288.
16. Ferguson, J. (1997) Medical director of prescription pricing. (Personal communication).
17. Fischl, M.A., Dickinson, M.A., Scott, G.B. et al (1987) Evaluation of heterosexual partners, children and household contacts of adults with AIDs. JAMA, 257, 640.
18. Fraser, I.S. and McCarron, G. (1991) Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust. N.Z. J. Obstet. Gynecol., 31, 66-70.
19. Grimes, G.A. (1986) Reversible contraception for the 1980s. JAMA, 255, 69-75.
20. Gottlieb, S. (1998) Breast cancer genes and the pill reduce cancer risk. Br. Med. J., 317, 489.
21. Guttmacher Institute (1998) Issues in Brief. The role of contraception in reducing abortion http://www.agi-usa.org 1-10..
22. Hatcher, R.A., Stewart, F., Trussel, J. et al. (1990-1992). Contracept. Technol., 13, 223.
23. Hope, S. (1996) 12% of women stopped taking their pill immediately they heard the CSM's warning. Lancet, 312, 576.
24. Jick, H., Jick, S., Gurewich, V. et al. (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet, 346, 1589-1593.
25. Jick, H., Jick, S., Meyers, M.W. and Vasilakis, C. (1996) Risk of acute myocardial infarction and low dose oral contraceptives (letter). Lancet, 347, 627-628.
26. Kubba, A. and Wilkinson, C. (1998) Recommendations for clinical practice. Emergency Contraception. Faculty of Family Planning and Reproductive Health Care. January 1998. Br. J. Family Planning, 23, 135-137.
27. Laffan, M. and Tuddenham, E. (1998) Assessing thrombotic risk. Br. Med. J., 317, 520-522.
28. Lewis, M.A., Heinemann, L.A.J., Spitzer, W.O. et al. (1997) For the Transnational Research Group on Oral Contraceptives and the Health of Young women. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational study on Oral Contraceptives and the Health of Young Women. Contraception, 56, 129-140.
29. Lidegaard, Ø. (1995) Decline in cerebral thrombosis among women after introduction of low dose oral contraception. An incidence study for the period 1980-93. Contraception, 52, 85-92.
30. Little, P., Griffin, S., Kelly, J. et al. (1998) Effects of educational leaflets and questions on knowledge of contraception in women taking the combined contraceptive pill: randomised controlled trial. Br. Med. J., 316, 1948-1952.
31. MacGregor, E.A. and Guillebaud, J. (1998) Recommendations for clinical practice. Combined oral contraceptives, migraine and ischaemic stroke. Br. J. Family Planning, 24, 53-60.
32. Maine, D. and McNamara, R. (1985) Birth spacing and child survival. The Centre for Population and Family Health, 1-30.
33. McNee, X. (1997) The Erice Declaration. http://www.who.pharmasoft.se/communications.htm).
34. Mills, A. (1997) Combined oral contraception and the risk of venous thromboembolism. Hum. Reprod., 12, 2595-2598.
35. Mills, A. and Edwards, I.R. (1999) The combined oral contraceptive pill - are poor communication systems responsible for loss of confidence in this contraceptive method? Hum. Reprod., 14, 7-10.
36. Mills, A.M., Wilkinson, C.L., Bromham, D.R. et al. (1996) Guidelines for prescribing the combined oral contraceptive pill. Br. Med. J., 312, 121-122.
37. Mills, A., Wilkinson, C. and Fotherby, K. (1998) Can a change in screening and prescribing practice reduce the risk of venous thromboembolism in women taking the combined oral contraceptive pill? Br. J. Family Planning, 23, 112-115.
38. Moore, J., Kennedy, K. and Prentice, A. (1997) Modern combined oral contraceptives for the treatment of painful symptoms associated with endometriosis. The Cochrane Library, issue 3, 1-7.
39. Narod, S. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study group. N. Engl. J. Med., 339, 424-428.
40. National Centre for Health Statistics, Vital Statistics of the United States, 1991: Vol. 11-Mortality, Part A, US Government Printing Office, Washington, DC, 1996. http://www.agi-usa.org).
41. New Scientist (1987) Sheaths no barrier. (Editorial). Vol. 1548, p. 12
42. Office for National Statistics (1997) ONS Monitor AB 97. London, UK.
43. Office for National Statistics: Mortality Statistics (1996) HMSO, London. Series DH2, 21, pp. 349, 358.
44. Office for Population Census and Statistics. Government Statistical Service. HMSO, London.
45. Overton, C., Hargreaves, J. and Maresh, M. (1997) A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study. Minimally invasive techniques - Laser, EndoThermal or Endoresection. Br. J. Obstet. Gynaecol., 104, 1351-1359.
46. Pabinger, I., Schneider, B. and the GTH Study Group on Natural Inhibitors (1994) Thrombotic risk of women with hereditary antithrombin 111, protein C and protein S deficiency taking oral contraceptives. Thromb. Haemost., 71, 548-552.
47. Rees, C.D., Cox, M. and Clegg, J.B. (1995) World distribution of factor V Leiden. Lancet, 346, 1133.
48. Reijnen, H.B.M. and Atsma, W.J. (1995) Risk is highest during first months of use. (Letter to the editor). Br. Med. J., 311, 1639.
49. Rosenberg, L., Palmer, J.R., Sands, M.I. et al. (1997) Modern oral contraceptives and cardiovascular disease. Am. J. Obstet. Gynecol., 177, 707-715.
50. Rosendaal, F.R. (1996) Oral contraceptives and screening for factor V Leiden. Thromb. Haemost., 75, 524-525.
51. Ryan, M. (1987) Illegal abortion and the Soviet Health Service. Br. Med. J., 294, 425-426.
52. Sidney, S., Petitti, D.B, Queensberry, C.P. et al. (1996) Myocardial infarction in users of low dose oral contraceptives. Obstet. Gynecol., 88, 939-944.
53. Skjeldestad, F.E. (1997) Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. Contraception, 55, 11-14.
54. Sonne-Holme, S., Heisterberg, L., Hebjorn, S. et al. (1981) Prophylactic antibiotics in first trimester abortions. A clinical controlled trial. Am. J. Obstet. Gynecol., 139, 639.
55. Spitzer, W.O., Lewis, M., Heinemann, L.A.J. et al., on behalf of the Transnational Research Group on oral contraceptives and the health of young women (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders. Br. Med. J., 312, 83-88.
56. Stadel, B.V. (1981) Oral contraceptives and cardiovascular disease. N. Engl. J. Med., 305, 612-617, 672-677.
57. Tzourio, C., Iglesias, S., Hubert, J.-B. et al. (1993) Migraine and risk of ischaemic stroke. Br. Med. J., 307, 289-292.
58. Vandenbroucke, J.P. (1998) Cerebral sinus thrombosis and oral contraceptives. Br. Med. J., 317, 483-484.
59. Vandenbroucke, J.P., Kosteer, T., Brier, P. et al. (1994) Increased risk of venous thromboembolism in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet, 344, 1453-1457.
60. Vandenbroucke, J.P., van der Meer, J.M., Helmerhorst, F.M. et al. (1996) Factor V Leiden: should we screen oral contraceptive users and pregnant women? Br. Med. J., 313, 1127-1130.
61. Vercellini, P., Trepidi, L., Colombo, A. et al. (1993) A gonadotrophin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil. Steril., 60, 75-79.
62. Vessey, M.P. (1980) Female hormones and vascular disease: epidemiological overview. Br. J. Family Planning, 6 (Suppl.), 1-12.
63. Vessey, M.P. (1989) The Jeffcott Lecture. An overview of the benefits and risks of combined oral contraceptives. In Mann, R.D. (ed.), Oral Contraceptives and Breast Cancer: The Implications of the Present Findings for Informed Consent and Informed Choice. The Parthenon Publishing Group, New Jersey, 1989, pp. 121-135.
64. Vessey, M., Metcalfe, A., Wells, C. et al. (1987) Ovarian neoplasms, functional ovarian cyst, and oral contraceptives. Br. Med. J., 294, 1518-1520.
65. World Health Organization (1995) Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low dose oral contraceptives on venous thromboembolic disease. Lancet, 346, 1582-1588.
66. World Health Organization (1996) Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case control study. Lancet, 348, 505-510.
67. World Health Organization (1997) Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international, multicentre, case control study. Lancet, 349, 1202-1209.
68. World Health Organization (1998) Emergency contraception. A guide for service delivery WHO/FRH/FPP/98/9.
69. Zahr, C.A. and Royston, E. (1991) Maternal mortality: a global factbook. World Health Organization, Geneva. WHO/MCH/MSM/91.3.